GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MiMedx Group Inc (NAS:MDXG) » Definitions » Cash Flow from Investing

MiMedx Group (MiMedx Group) Cash Flow from Investing : $-7.5 Mil (TTM As of Mar. 2024)


View and export this data going back to 2008. Start your Free Trial

What is MiMedx Group Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Mar. 2024, MiMedx Group spent $1.1 Mil on purchasing property, plant, equipment. It gained $0.0 Mil from selling property, plant, and equipment. It spent $0.0 Mil on purchasing business. It gained $0.0 Mil from selling business. It spent $0.0 Mil on purchasing investments. It gained $0.0 Mil from selling investments. It paid $5.0Mil for net Intangibles purchase and sale. And it received $0.1 Mil from other investing activities. In all, MiMedx Group spent $6.0 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Mar. 2024.


MiMedx Group Cash Flow from Investing Historical Data

The historical data trend for MiMedx Group's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MiMedx Group Cash Flow from Investing Chart

MiMedx Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.50 -4.56 -3.40 -2.66 -2.16

MiMedx Group Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.68 -0.35 -0.65 -0.48 -6.02

MiMedx Group Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

MiMedx Group's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:

MiMedx Group's Cash Flow from Investing for the quarter that ended in Mar. 2024 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MiMedx Group  (NAS:MDXG) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

MiMedx Group's purchase of property, plant, equipment for the three months ended in Mar. 2024 was $-1.1 Mil. It means MiMedx Group spent $1.1 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

MiMedx Group's sale of property, plant, equipment for the three months ended in Mar. 2024 was $0.0 Mil. It means MiMedx Group gained $0.0 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

MiMedx Group's purchase of business for the three months ended in Mar. 2024 was $0.0 Mil. It means MiMedx Group spent $0.0 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

MiMedx Group's sale of business for the three months ended in Mar. 2024 was $0.0 Mil. It means MiMedx Group gained $0.0 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

MiMedx Group's purchase of investment for the three months ended in Mar. 2024 was $0.0 Mil. It means MiMedx Group spent {stock_data.stock.currency_symbol}}0.0 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

MiMedx Group's sale of investment for the three months ended in Mar. 2024 was $0.0 Mil. It means MiMedx Group gained $0.0 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

MiMedx Group's net Intangibles purchase and sale for the three months ended in Mar. 2024 was $-5.0 Mil. It means MiMedx Group paid $5.0 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

MiMedx Group's cash from discontinued investing activities for the three months ended in Mar. 2024 was 0.0 Mil. It means MiMedx Group paid $0.0 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

MiMedx Group's cash from other investing activities for the three months ended in Mar. 2024 was $0.1 Mil. It means MiMedx Group received $0.1 Mil from other investing activities.


MiMedx Group Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of MiMedx Group's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


MiMedx Group (MiMedx Group) Business Description

Traded in Other Exchanges
N/A
Address
1775 West Oak Commons Court, NE, Marietta, GA, USA, 30062
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, MiMedx sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
Executives
Rice Doug officer: Chief Financial Officer 3451 PLANO PARKWAY, LEWISVILLE TX 75056
Joseph H Capper officer: Chief Executive Officer BIOTELEMETRY, INC., 1000 CEDAR HOLLOW ROAD, #102, MALVERN PA 19355
Robert Benjamin Stein officer: EVP, Research and Development C/O AGENUS INC., 3 FORBES ROAD, LEXINGTON MA 02421
Peter M Carlson officer: Chief Financial Officer BRIGHTHOUSE FINANCIAL, INC., 11225 NORTH COMMUNITY HOUSE ROAD, CHARLOTTE NC 28277
William Lawrence Phelan officer: Chief Accounting Officer 1775 WEST OAK COMMONS COURT NE, MARIETTA GA 30062
Hulse William Frank Iv officer: General Counsel 1775 WEST OAK COMMONS COURT NE, MARIETTA GA 30062
Ricci S Whitlow officer: Chief Operating Officer C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Rohit Kashyap officer: EVP & Chief Commercial Officer 8023 VANTAGE DRIVE, SAN ANTONIO TX 78230
Timothy R Wright director, officer: Chief Executive Officer C/O CURAXIS, 1004 CHAGFORD WAY, RALEIGH NC 27614
Mark Graves officer: SVP & Chief Compliance Officer 1775 WEST OAK COMMONS COURT, MARIETTA GA 30062
Scott M Turner officer: SVP, Operations & Procurement 1775 WEST OAK COMMONS COURT, MARIETTA GA 30062
Phyllis Gardner director 618 MIRADA AVENUE, STANFORD CA 94305
Michael J Giuliani director 1775 WEST OAK COMMONS COURT NE, MARIETTA GA 30062
Cato T Laurencin director C/O UNIVERSITY OF CONNECTICUT, 263 FARMINGTON AVENUE, FARMINGTON CT 06030-3800
William A Hawkins director MEDTRONIC INC, 710 MEDTRONIC PKWY, MS LC310, MINNEAPOLIS MN 55432-5604